TapewireFind a company

person · Reporting owner

Molineaux Susan

Disclosed activity across 5 companies

Tapewire entity
44452
SEC CIK
0001553389

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Calithera Biosciences, Inc.CALA · Entity 113073Director · PRESIDENT & CEOJanuary 23, 2023January 25, 2023
Cyteir Therapeutics, Inc.CYT · Entity 92707DirectorFebruary 03, 2023February 07, 2023
GERON CORPGERN · Entity 4989DirectorMay 20, 2026May 26, 2026
Repare Therapeutics Inc.RPTX · Entity 68433DirectorJune 17, 2024June 20, 2024
Theravance Biopharma, Inc.TBPH · Entity 5037DirectorApril 27, 2021April 29, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Calithera Biosciences, Inc.

Report date January 23, 2023 · Filed January 25, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Trust27,859 Reported balance After 2023-01-23 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2023-01-23 · Tax withholding · Disposed 526 · Balance 27,859

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on January 23, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

F3: Shares are held by the Molineaux Family Trust of which the Reporting Person is a Trustee.

Common StockSEC Table I · non-derivativeIndirectBy Spouse5,283 Reported balance Holding disclosure · report date 2023-01-23 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 5,283

Common StockSEC Table I · non-derivativeDirect4,724 Reported balance Holding disclosure · report date 2023-01-23 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 4,724

F4: Includes 125 shares acquired on each of December 10, 2021, June 10, 2022 and December 9, 2022, under the Company's 2014 Employee Stock Purchase Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on January 23, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

F3: Shares are held by the Molineaux Family Trust of which the Reporting Person is a Trustee.

F4: Includes 125 shares acquired on each of December 10, 2021, June 10, 2022 and December 9, 2022, under the Company's 2014 Employee Stock Purchase Plan.

Cyteir Therapeutics, Inc.

Report date February 03, 2023 · Filed February 07, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03Direct14,150 Reported balance After 2023-02-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-02-03 · Grant · Acquired 14,150 · Balance 14,150

F1: The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date.

GERON CORP

Report date May 20, 2026 · Filed May 26, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2036-05-19Direct220,000 Reported balance After 2026-05-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-05-20 · Grant · Acquired 220,000 · Balance 220,000

F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates.

Filing footnotes · ownership attribution and instrument terms

F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates.

Repare Therapeutics Inc.

Report date June 17, 2024 · Filed June 20, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2034-06-16Direct27,200 Reported balance After 2024-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-06-17 · Grant · Acquired 27,200 · Balance 27,200

F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.

Theravance Biopharma, Inc.

Report date April 27, 2021 · Filed April 29, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect9,828 Reported balance After 2021-04-27 transaction · row 1
1 source row

Row 1 · 2021-04-27 · Grant · Acquired 9,828 · Balance 9,828

Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.35 · Expires 2031-04-26Direct6,000 Reported balance After 2021-04-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2021-04-27 · Grant · Acquired 6,000 · Balance 6,000

F1: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date.

Ordinary SharesSEC Table I · non-derivativeIndirectBy Family Trust41,206 Reported balance Holding disclosure · report date 2021-04-27 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 41,206

Filing footnotes · ownership attribution and instrument terms

F1: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 20, 2026 Filed May 26, 2026 23:45 UTC GERON CORP GERN · Entity 4989 GrantStock Option (right to buy) · Derivative 220,000 $0.00 Strike: $1.26 $0.00
Disclosure

SEC source: 0001553389-26-000002 · form4-05262026_070505.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,000

Underlying: Common Stock · 220,000 shares

Expires 2036-05-19

F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates.

Read SEC document
May 21, 2025 Filed May 22, 2025 21:02 UTC GERON CORP GERN · Entity 4989 GrantStock Option (right to buy) · Derivative 180,000 $0.00 Strike: $1.34 $0.00
Disclosure

SEC source: 0000886744-25-000023 · wk-form4_1747947757.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2035-05-20

F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates.

Read SEC document
June 17, 2024 Filed Jun 20, 2024 20:35 UTC Repare Therapeutics Inc. RPTX · Entity 68433 GrantStock Option (right to buy) · Derivative 27,200 $0.00 Strike: $3.80 $0.00
Disclosure

SEC source: 0001415889-24-017657 · form4-06202024_040611.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,200

Underlying: Common Shares · 27,200 shares

Expires 2034-06-16

F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.

Read SEC document
May 09, 2024 Filed May 10, 2024 20:05 UTC GERON CORP GERN · Entity 4989 GrantStock Option (right to buy) · Derivative 180,000 $0.00 Strike: $3.88 $0.00
Disclosure

SEC source: 0000950170-24-057798 · ownership.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2034-05-08

F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates.

Read SEC document
December 29, 2023 Filed Jan 4, 2024 00:04 UTC GERON CORP GERN · Entity 4989 GrantCommon Stock 6,220 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-000546 · doc4.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 130,527

F1 · kind: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on closing price of the Issuer's Common Stock on December 29, 2023 of $2.11 per share.

F1 · price: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on closing price of the Issuer's Common Stock on December 29, 2023 of $2.11 per share.

Read SEC document
September 29, 2023 Filed Oct 2, 2023 23:32 UTC GERON CORP GERN · Entity 4989 GrantCommon Stock 6,191 $0.00 $0.00
Disclosure

SEC source: 0001062993-23-018726 · form4.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Family Trust

Disclosed balance after: 124,307

F1 · kind: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on closing price of Geron Common Stock on September 29, 2023 of $2.12 per share.

F1 · price: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on closing price of Geron Common Stock on September 29, 2023 of $2.12 per share.

Read SEC document
June 30, 2023 Filed Jul 1, 2023 01:19 UTC GERON CORP GERN · Entity 4989 GrantCommon Stock 4,088 $0.00 $0.00
Disclosure

SEC source: 0001062993-23-014272 · form4.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Family Trust

Disclosed balance after: 118,116

F1 · kind: Shares issued in lieu of cash payment for annual board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on June 30, 2023 of $3.21 per share.

F1 · price: Shares issued in lieu of cash payment for annual board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on June 30, 2023 of $3.21 per share.

Read SEC document
June 08, 2023 Filed Jun 12, 2023 20:26 UTC Repare Therapeutics Inc. RPTX · Entity 68433 GrantStock Option (right to buy) · Derivative 76,200 $0.00 Strike: $11.66 $0.00
Disclosure

SEC source: 0001209191-23-036313 · doc4.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,200

Underlying: Common Shares · 76,200 shares

Expires 2033-06-07

F1 · derivative.exercise_date: One-third (1/3rd) of the shares subject to the option shall vest on June 8, 2024, and one twenty-fourth (1/24th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.

Read SEC document
May 31, 2023 Filed Jun 2, 2023 23:34 UTC GERON CORP GERN · Entity 4989 GrantStock Option (right to buy) · Derivative 125,000 $0.00 Strike: $3.27 $0.00
Disclosure

SEC source: 0001062993-23-012819 · form4.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2033-05-30

F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates.

Read SEC document
May 01, 2023 Filed May 2, 2023 01:20 UTC GERON CORP GERN · Entity 4989 Exercise / conversionStock Options (right to buy) · Derivative 35,000 $0.00 Strike: $1.10 $0.00
Disclosure

SEC source: 0001062993-23-009883 · form4.xml · derivative · entry 3

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,000 shares

Expires 2023-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 17, 2023.

F1 · derivative.exercise_date: Option was fully vested.

Read SEC document
May 01, 2023 Filed May 2, 2023 01:20 UTC GERON CORP GERN · Entity 4989 SaleCommon Stock 35,000 $2.48 $86,800.00
Disclosure

SEC source: 0001062993-23-009883 · form4.xml · nonDerivative · entry 2

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 17, 2023.

Read SEC document
May 01, 2023 Filed May 2, 2023 01:20 UTC GERON CORP GERN · Entity 4989 Exercise / conversionCommon Stock 35,000 $1.10 $38,500.00
Disclosure

SEC source: 0001062993-23-009883 · form4.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This transaction reflects an exercise and sale of options due to expire on May 22, 2023 and was conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on February 17, 2023.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 00:47 UTC GERON CORP GERN · Entity 4989 GrantCommon Stock 6,048 $0.00 $0.00
Disclosure

SEC source: 0001062993-23-008380 · form4.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Family Trust

Disclosed balance after: 114,028

F1 · kind: Shares issued in lieu of cash payment for annual board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on March 31, 2023 of $2.17 per share.

F1 · price: Shares issued in lieu of cash payment for annual board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on March 31, 2023 of $2.17 per share.

Read SEC document
February 03, 2023 Filed Feb 7, 2023 16:44 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 GrantStock Option (Right to Buy) · Derivative 14,150 $0.00 Strike: $1.69 $0.00
Disclosure

SEC source: 0001209191-23-007547 · doc4.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires 2033-02-03

F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date.

Read SEC document
January 23, 2023 Filed Jan 25, 2023 16:00 UTC Calithera Biosciences, Inc. CALA · Entity 113073 Tax withholdingCommon Stock 526 $0.45 $234.65
Disclosure

SEC source: 0000899243-23-002610 · doc4.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 27,859

F1 · shares: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on January 23, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

F3 · ownership.nature: Shares are held by the Molineaux Family Trust of which the Reporting Person is a Trustee.

Read SEC document
May 10, 2022 Filed May 11, 2022 22:17 UTC GERON CORP GERN · Entity 4989 GrantStock Option (right to buy) · Derivative 125,000 $0.00 Strike: $1.48 $0.00
Disclosure

SEC source: 0001062993-22-012157 · form4.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2032-05-09

F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates.

Read SEC document
February 22, 2022 Filed Feb 24, 2022 17:01 UTC Cyteir Therapeutics, Inc. CYT · Entity 92707 GrantStock Option (Right to Buy) · Derivative 14,150 $0.00 Strike: $5.96 $0.00
Disclosure

SEC source: 0000899243-22-007650 · doc4.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires 2032-02-22

F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on February 22, 2023, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date.

Read SEC document
January 25, 2022 Filed Jan 27, 2022 18:41 UTC Calithera Biosciences, Inc. CALA · Entity 113073 GrantEmployee Stock Option (Right to Buy) · Derivative 597,475 $0.00 Strike: $0.44 $0.00
Disclosure

SEC source: 0000899243-22-003487 · doc4.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 597,475

Underlying: Common Stock · 597,475 shares

Expires 2032-01-24

F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 25, 2022; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Read SEC document
November 10, 2021 Filed Nov 10, 2021 19:34 UTC Calithera Biosciences, Inc. CALA · Entity 113073 PurchaseCommon Stock 100,000 $0.85 $84,670.00
Disclosure

SEC source: 0000899243-21-044154 · doc4.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 557,188

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8152 to $0.8791, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F2 · ownership.nature: Shares are held by the Molineaux Family Trust of which the Reporting Person is a Trustee.

Read SEC document
May 11, 2021 Filed May 14, 2021 01:20 UTC GERON CORP GERN · Entity 4989 GrantStock Option (right to buy) · Derivative 83,000 $0.00 Strike: $1.39 $0.00
Disclosure

SEC source: 0000886744-21-000036 · edgar.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,000

Underlying: Common Stock · 83,000 shares

Expires 2031-05-10

F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates.

Read SEC document
April 27, 2021 Filed Apr 29, 2021 22:13 UTC Theravance Biopharma, Inc. TBPH · Entity 5037 GrantShare Option (Right to Buy) · Derivative 6,000 $0.00 Strike: $20.35 $0.00
Disclosure

SEC source: 0001179110-21-004701 · edgar.xml · derivative · entry 3

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Ordinary Shares · 6,000 shares

Expires 2031-04-26

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date.

Read SEC document
April 27, 2021 Filed Apr 29, 2021 22:13 UTC Theravance Biopharma, Inc. TBPH · Entity 5037 GrantOrdinary Shares 9,828 $0.00 $0.00
Disclosure

SEC source: 0001179110-21-004701 · edgar.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,828

Read SEC document
January 20, 2021 Filed Jan 22, 2021 20:37 UTC Calithera Biosciences, Inc. CALA · Entity 113073 GrantEmployee Stock Option (Right to Buy) · Derivative 375,000 $0.00 Strike: $2.98 $0.00
Disclosure

SEC source: 0000899243-21-003050 · doc4.xml · derivative · entry 4

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 375,000

Underlying: Common Stock · 375,000 shares

Expires 2031-01-20

F4 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 20, 2021; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Read SEC document
January 20, 2021 Filed Jan 22, 2021 20:37 UTC Calithera Biosciences, Inc. CALA · Entity 113073 GrantCommon Stock 85,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-003050 · doc4.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,000

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest as follows: one-fourth (1/4th) of the shares subject to the Restricted Stock Unit will vest each year after January 20, 2021 until the Restricted Stock Units are fully vested. The Restricted Stock Unit shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

F2 · balance_after: Includes 2,500 shares acquired on each of December 10, 2019, June 10, 2020, and December 10, 2020 under the Company's 2014 Employee Stock Purchase Plan.

Read SEC document
June 05, 2020 Filed Jun 9, 2020 22:13 UTC GERON CORP GERN · Entity 4989 GrantStock Option (right to buy) · Derivative 83,000 $0.00 Strike: $1.54 $0.00
Disclosure

SEC source: 0000886744-20-000050 · edgar.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,000

Underlying: Common Stock · 83,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates.

Read SEC document
April 28, 2020 Filed Apr 30, 2020 23:56 UTC Theravance Biopharma, Inc. TBPH · Entity 5037 GrantShare Option (Right to Buy) · Derivative 6,000 $0.00 Strike: $30.14 $0.00
Disclosure

SEC source: 0001179110-20-005320 · edgar.xml · derivative · entry 3

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Ordinary Shares · 6,000 shares

Expires 2030-04-27

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date.

Read SEC document
April 28, 2020 Filed Apr 30, 2020 23:56 UTC Theravance Biopharma, Inc. TBPH · Entity 5037 GrantOrdinary Shares 6,635 $0.00 $0.00
Disclosure

SEC source: 0001179110-20-005320 · edgar.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,635

Read SEC document
January 18, 2020 Filed Jan 22, 2020 18:17 UTC Calithera Biosciences, Inc. CALA · Entity 113073 GrantEmployee Stock Option (Right to Buy) · Derivative 400,000 $0.00 Strike: $7.41 $0.00
Disclosure

SEC source: 0000899243-20-001696 · doc4.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2030-01-18

F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 17, 2020; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Read SEC document
June 25, 2019 Filed Jun 27, 2019 16:05 UTC Calithera Biosciences, Inc. CALA · Entity 113073 PurchaseCommon Stock 51,600 $3.88 $200,208.00
Disclosure

SEC source: 0000899243-19-018344 · doc4.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 457,188

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.8278 to $3.8938. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F2 · balance_after: Includes 2,500 shares acquired under the Company's 2014 Employee Stock Purchase Plan on December 10, 2018.

F3 · ownership.nature: Shares are held by the Molineaux Family Trust, of which the Reporting Person is a Trustee, including 5,000 shares transferred from the Reporting Person and 5,000 shares transferred from the Reporting Person's spouse, to the Molineaux Family Trust on March 27, 2019.

Read SEC document
June 06, 2019 Filed Jun 7, 2019 23:24 UTC GERON CORP GERN · Entity 4989 GrantStock Option (right to buy) · Derivative 70,000 $0.00 Strike: $1.38 $0.00
Disclosure

SEC source: 0000886744-19-000063 · edgar.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2029-06-05

F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates.

Read SEC document
April 30, 2019 Filed May 2, 2019 22:44 UTC Theravance Biopharma, Inc. TBPH · Entity 5037 GrantShare Option (Right to Buy) · Derivative 6,000 $0.00 Strike: $23.85 $0.00
Disclosure

SEC source: 0001179110-19-005477 · edgar.xml · derivative · entry 3

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Ordinary Shares · 6,000 shares

Expires 2029-04-29

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date.

Read SEC document
April 30, 2019 Filed May 2, 2019 22:44 UTC Theravance Biopharma, Inc. TBPH · Entity 5037 GrantOrdinary Shares 8,385 $0.00 $0.00
Disclosure

SEC source: 0001179110-19-005477 · edgar.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,385

Read SEC document
February 07, 2019 Filed Feb 11, 2019 16:05 UTC Calithera Biosciences, Inc. CALA · Entity 113073 GiftCommon Stock 12,986 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-003138 · doc4.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 395,588

F1 · shares: Represents shares transferred to the Reporting Person's children. The securities owned by the children are not beneficially owned by the Reporting Person.

F2 · ownership.nature: Shares are held by the Molineaux Family Trust, of which the Reporting Person is a Trustee

Read SEC document
January 10, 2019 Filed Jan 14, 2019 16:33 UTC Calithera Biosciences, Inc. CALA · Entity 113073 GrantEmployee Stock Option (Right to Buy) · Derivative 390,000 $0.00 Strike: $4.64 $0.00
Disclosure

SEC source: 0000899243-19-001133 · doc4.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 390,000

Underlying: Common Stock · 390,000 shares

Expires 2029-01-09

F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 10, 2019; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Read SEC document
December 31, 2018 Filed Jan 3, 2019 00:23 UTC GERON CORP GERN · Entity 4989 GrantCommon Stock 13,125 $0.00 $0.00
Disclosure

SEC source: 0000886744-19-000005 · edgar.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Family Trust

Disclosed balance after: 107,980

F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 31, 2018 of $1.00 per share.

F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 31, 2018 of $1.00 per share.

F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 31, 2018 of $1.00 per share.

Read SEC document
November 14, 2018 Filed Nov 16, 2018 16:07 UTC Calithera Biosciences, Inc. CALA · Entity 113073 GiftCommon Stock 6,476 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-029127 · doc4.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 408,574

F1 · shares: Represents shares transferred to the Reporting Person's children. The securities owned by the children are not beneficially owned by the Reporting Person.

F2 · ownership.nature: Shares are held by the Molineaux Family Trust, of which the Reporting Person is a Trustee, including 44,860 shares transferred from the Reporting Person to the Trust on April 10, 2018.

Read SEC document
September 28, 2018 Filed Sep 29, 2018 00:03 UTC GERON CORP GERN · Entity 4989 GrantCommon Stock 7,457 $0.00 $0.00
Disclosure

SEC source: 0000886744-18-000053 · edgar.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Family Trust

Disclosed balance after: 94,855

F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 28, 2018 of $1.76 per share.

F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 28, 2018 of $1.76 per share.

F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 28, 2018 of $1.76 per share.

Read SEC document
June 29, 2018 Filed Jul 2, 2018 22:37 UTC GERON CORP GERN · Entity 4989 GrantCommon Stock 3,827 $0.00 $0.00
Disclosure

SEC source: 0000886744-18-000041 · edgar.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Family Trust

Disclosed balance after: 87,398

F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 29, 2018 of $3.43 per share.

F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 29, 2018 of $3.43 per share.

F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 29, 2018 of $3.43 per share.

Read SEC document
May 15, 2018 Filed May 17, 2018 20:48 UTC GERON CORP GERN · Entity 4989 GrantStock Option (right to buy) · Derivative 70,000 $0.00 Strike: $3.43 $0.00
Disclosure

SEC source: 0000886744-18-000035 · edgar.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2028-05-14

F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates.

Read SEC document
May 01, 2018 Filed May 3, 2018 22:16 UTC Theravance Biopharma, Inc. TBPH · Entity 5037 GrantShare Option (Right to Buy) · Derivative 6,000 $0.00 Strike: $24.43 $0.00
Disclosure

SEC source: 0001179110-18-006192 · edgar.xml · derivative · entry 3

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Ordinary Shares · 6,000 shares

Expires 2028-04-30

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date.

Read SEC document
May 01, 2018 Filed May 3, 2018 22:16 UTC Theravance Biopharma, Inc. TBPH · Entity 5037 GrantOrdinary Shares 8,186 $0.00 $0.00
Disclosure

SEC source: 0001179110-18-006192 · edgar.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,186

Read SEC document
March 29, 2018 Filed Mar 30, 2018 22:06 UTC GERON CORP GERN · Entity 4989 GrantCommon Stock 3,088 $0.00 $0.00
Disclosure

SEC source: 0000886744-18-000023 · edgar.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Family Trust

Disclosed balance after: 83,571

F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2018 of $4.25 per share.

F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2018 of $4.25 per share.

F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2018 of $4.25 per share.

Read SEC document
March 02, 2018 Filed Mar 6, 2018 16:12 UTC Calithera Biosciences, Inc. CALA · Entity 113073 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 6,798 $0.00 Strike: $2.64 $0.00
Disclosure

SEC source: 0000899243-18-006476 · doc4.xml · derivative · entry 5

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 0

Underlying: Common Stock · 6,798 shares

Expires 2023-12-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Read SEC document
March 02, 2018 Filed Mar 6, 2018 16:12 UTC Calithera Biosciences, Inc. CALA · Entity 113073 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 26,992 $0.00 Strike: $2.64 $0.00
Disclosure

SEC source: 0000899243-18-006476 · doc4.xml · derivative · entry 4

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,729

Underlying: Common Stock · 26,992 shares

Expires 2023-12-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Read SEC document
March 02, 2018 Filed Mar 6, 2018 16:12 UTC Calithera Biosciences, Inc. CALA · Entity 113073 Exercise / conversionCommon Stock 26,992 $2.64 $71,258.88
Disclosure

SEC source: 0000899243-18-006476 · doc4.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,860

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 2,500 shares acquired under the Company's 2014 Employee Stock Purchase Plan on December 8, 2017.

Read SEC document
January 11, 2018 Filed Jan 16, 2018 16:05 UTC Calithera Biosciences, Inc. CALA · Entity 113073 GrantEmployee Stock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $8.60 $0.00
Disclosure

SEC source: 0000899243-18-001072 · doc4.xml · derivative · entry 1

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2028-01-10

F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after January 11, 2018; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Read SEC document
December 29, 2017 Filed Jan 2, 2018 23:21 UTC GERON CORP GERN · Entity 4989 GrantCommon Stock 7,292 $0.00 $0.00
Disclosure

SEC source: 0000886744-18-000002 · edgar.xml · nonDerivative · entry 1

Molineaux Susan · CIK 0001553389 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Family Trust

Disclosed balance after: 80,483

F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 29, 2017 of $1.80 per share.

F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 29, 2017 of $1.80 per share.

F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 29, 2017 of $1.80 per share.

Read SEC document
December 05, 2017 Filed Dec 6, 2017 16:05 UTC Calithera Biosciences, Inc. CALA · Entity 113073 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 2,700 $0.00 Strike: $2.64 $0.00
Disclosure

SEC source: 0000899243-17-028063 · doc4.xml · derivative · entry 8

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 6,006

Underlying: Common Stock · 2,700 shares

Expires 2023-12-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Read SEC document
December 05, 2017 Filed Dec 6, 2017 16:05 UTC Calithera Biosciences, Inc. CALA · Entity 113073 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 6,502 $0.00 Strike: $0.96 $0.00
Disclosure

SEC source: 0000899243-17-028063 · doc4.xml · derivative · entry 7

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 0

Underlying: Common Stock · 6,502 shares

Expires 2023-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Read SEC document
December 05, 2017 Filed Dec 6, 2017 16:05 UTC Calithera Biosciences, Inc. CALA · Entity 113073 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 5,300 $0.00 Strike: $2.64 $0.00
Disclosure

SEC source: 0000899243-17-028063 · doc4.xml · derivative · entry 6

Molineaux Susan · CIK 0001553389 · Director · PRESIDENT AND CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,030

Underlying: Common Stock · 5,300 shares

Expires 2023-12-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.